Balanced news tone
News Sentiment
ATOS sentiment intelligence
Atossa Genetics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+11.8% over one week, -3.7% over four weeks, trend inactive, and below fair value.
Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Biotech Atossa targets up to $16.5M to fund clinical work
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Stock Titan
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 16:51
- Source
- Proactive
CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 09:05
- Source
- Zacks Small Cap Research
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- PR Newswire
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- PR Newswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 12:30
- Source
- PR Newswire
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Atossa Therapeutics (NASDAQ: ATOS) wins OK for potential reverse stock split
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Stock Titan
Atossa Genetics stock surges after FDA rare disease designation
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Investing.com
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Atossa Genetics rated more favorable than Hyper...
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Mar 2026 07:00
- Source
- Pluang
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Feb 2026 08:00
- Source
- Market source
Atossa Genetics (ATOS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ATOS
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2025 17:04
- Source
- MarketBeat
Atossa Therapeutics secures new patent for breast cancer drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Apr 2025 07:00
- Source
- Investing.com
Atossa Genetics (ATOS) Stock Forecast and Price Target 2026 $ATOS
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 11 May 2024 16:27
- Source
- MarketBeat
Atossa Genetics (ATOS) Stock Price, News & Analysis $ATOS
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Aug 2016 18:04
- Source
- MarketBeat
Atossa Genetics Announces FDA Acceptance of Its
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Sep 2015 07:00
- Source
- GlobeNewswire
Breast cancer tests: an interview with Dr Steven Quay, CEO of Atossa Genetics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Feb 2013 08:00
- Source
- News-Medical